Grifols stock closed at €11.23 on 3 November, capping a 30 day gain of about 17.8%. That is the short term story. The real drama sits on the balance sheet. Q3 2026 produced €2.04b in revenue and helped lift trailing 12 month earnings to €472m, yet interest expenses still weigh heavily and keep financial risk in focus.
Short term traders are reacting to the bounce. Longer term investors are eyeing the 16.2x P/E against the company’s internal discounted cash flow value and asking a different question: how much balance sheet strain are they willing to underwrite for that apparent discount?
Love the earnings recovery at Grifols but worried about the debt load and interest bill that come with it? Instead, you can filter for a tighter mix of resilient cash flows and cleaner balance sheets with our list of solid balance sheet and fundamentals stocks (196 results)
Prefer clear, visual charts instead of wading through dense earnings tables and footnotes for Grifols? View the full financial picture with a focus on the balance sheet in an easy-to-read dashboard through our company report for Grifols.
Bulls argue Grifols only works if execution tightens around plasma costs, margins and leverage.
"The main thing that has to go right is continued execution on plasma self sufficiency, cost discipline and debt reduction so that free cash flow and adjusted EBITDA margins stay aligned with the multi year targets management has set."
On this score, the latest quarter shows some concrete markers. Adjusted EBITDA reached €538m, with margin up 60 bps year on year, and management reiterated a 25% full year target. Free cash flow before M&A was €298m year to date, with conversion above 20%. Net leverage moved just below 4x after the redemption of €500m of higher cost debt.
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for.
Bearish investors argue Grifols is one regulatory setback away from stalling its cash engine.
"While free cash flow before M&A reached €468 million in 2025 and remained positive at €91 million in H1 2026, any reversal of this trend due to sustained regulatory disruption in Canada, ongoing albumin price pressure in China or higher compliance costs around plasma collection could stall deleveraging, keep interest costs elevated and weigh on future earnings quality."
Q3 figures show free cash flow pre M&A at €298m year to date and net leverage at 3.98x, so deleveraging is progressing. The risk is that albumin weakness in China is already visible and Canada collections remain paused, so the feared pressure points are present even as cash conversion improves.
Grifols shows how a cleaner quarter can still leave investors debating balance sheet strain. The real opportunity is finding stocks that could be undervalued before the market corrects them.
Three companies from the same screener. Open the full list of 195 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com